Norio Nakatsuji/X
Jun 20, 2026, 07:09
Norio Nakatsuji: LRP5 Inhibition Shows Promise for Safer Blood-Thinning Strategies
Norio Nakatsuji, Professor Emeritus at Kyoto University, Director General at Nakatsuji Foresight Foundation, Chief Advisor at Stem Cell and Device Lab, Inc. Bluesky, shared on X:
”LRP5 Inhibition Shows Promise for Safer Blood-Thinning Strategies
‘LRP5 inhibition reduced platelet activation and thrombosis with lower bleeding impact than current drugs.”’
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering